Carcinoid syndrome other imaging findings

Jump to navigation Jump to search

Carcinoid syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Carcinoid Syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Carcinoid syndrome other imaging findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Carcinoid syndrome other imaging findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Carcinoid syndrome other imaging findings

CDC on Carcinoid syndrome other imaging findings

Carcinoid syndrome other imaging findings in the news

Blogs on Carcinoid syndrome other imaging findings

Directions to Hospitals Treating Carcinoid syndrome

Risk calculators and risk factors for Carcinoid syndrome other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

Other imaging studies for carcinoid tumor include somatostatin scintigraphy with 111Indium-octreotide, bone scintigraphy with 99mTc-methylene diphosphonate (99mTcMDP), 123 I-metaiodobenzylguanidine (MIBG) scintigraphy, capsule endoscopy (CE), enteroscopy, and angiography.

Other Imaging Findings

Other imaging modalities for gastrointestinal carcinoids include the use of:[1]

Somatostatin Receptor Scintigraphy

  • It is the gold-standard in confirming the location of functioning neuroendocrine tumour tissue.[2]
  • There are five different somatostatin receptor (SSTR) subtype, more than 70% of neuroendocrine tumors of both the gastrointestinal tract and pancreas express multiple subtypes predominantly 2 and 5.
  • Mid-gut carcinoids predominantly express somatostatin receptors from sub-group 2 (sst2).[3]
  • The synthetic radiolabeled SSTR analog 111In-DTP-d-Phe10-{octreotide} affords an important method, somatostatin receptor scintigraphy (SRS), to localize carcinoid tumors, especially sst(2)-positive and sst(5)-positive tumors, imaging is accomplished in one session, and small primary tumors and metastases are diagnosed more readily than with conventional imaging or imaging techniques requiring multiple sessions.
  • Overall sensitivity of the octreotide scan is reported to be as high as 90%.

Bone Scintigraphy

  • Bone scintigraphy with 99mTcMDP is the primary imaging modality for identifying bone involvement in neuroendocrine tumors and detection rates are reported to be 90% or higher.
  • 123I-MIBG is concentrated by carcinoid tumors in as many as 70% of cases using the same mechanism as norepinephrine and is used successfully to visualize carcinoids.
  • However, 123I-MIBG appears to be about half as sensitive as 111In-octreotide scintigraphy in detecting tumors.

Endoscopic Ultrasonography (EUS)

Endoscopic ultrasonography (EUS) may be a sensitive method for the detection of gastric and duodenal carcinoids and may be superior to conventional ultrasound, particularly in the detection of small tumors (2 mm–3 mm) that are localized in the bowel lumen. In one study, the EUS was reported to have an accuracy of 90% for the localization and staging of colorectal carcinoids.

Positron Emission Tomography–Computed Tomography

PET-CT is now playing an ever-increasing role in both localizing disseminated cancer and monitoring the disease response to systemic therapies.

  • Carcinoid-specific agents includes: 5-hydroxy-l-tryptophan (5-HTP),64Cu-1,4,8,11-tetra-azacyclo-tetradecane-N,N′,N″, N‴-tera-acetic acid (TETA-OC) and 18F-dopa have been used.

Angiography

MRI angiography has replaced angiography to a large extent. However, selective angiography may be useful to:

  • Demonstrate the degree of tumor vascularity
  • Identify the sources of vascular supply
  • Delineate the relationship of the tumor to adjacent major vascular structures
  • Provide information regarding vascular invasion

References

  1. Diagnostics: Biochemical Markers, Imaging, and Approach . National Cancer Institute. http://www.cancer.gov/types/gi-carcinoid-tumors/hp/gi-carcinoid-treatment-pdq#link/_49_toc Accessed on September 23, 2015
  2. Savelli, Giordano; Lucignani, Giovanni; Seregni, Ettore; Marchian??, Alfonso; Serafini, Gianluca; Aliberti, Gianluca; Villano, Carlo; Maccauro, Marco; Bombardieri, Emilio (2004). "Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours". Nuclear Medicine Communications. 25 (5): 445–449. doi:10.1097/00006231-200405000-00004. ISSN 0143-3636.
  3. Hashemi SH, Benjegård SA, Ahlman H, Wängberg B, Forssell-Aronsson E, Billig H, Nilsson O (May 2003). "111In-labelled octreotide binding by the somatostatin receptor subtype 2 in neuroendocrine tumours". Br J Surg. 90 (5): 549–54. doi:10.1002/bjs.4069. PMID 12734860.

Template:WS Template:WH